Investigations of covalent binding efficiency for third-generation EGFR irreversible inhibitors AZD9291 and CO-1686

被引：0
|
作者：
Qin, Zhen [1 ]
Sun, Xuebing [1 ]
Liu, Ye [1 ]
Du, Yunguang [1 ]
Wang, Miao [1 ]
Hu, Nan [1 ]
Zhang, Jiye [1 ]
Peng, Hao [1 ]
Wang, Lai [1 ]
Wei, Min [1 ]
Luo, Lusong [1 ]
机构：
[1] BeiGene Beijing Co Ltd, Beijing, Peoples R China
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2589
引用
收藏
页数：2
相关论文
共 16 条
  • [1] Lentiviral Insertional Mutagenesis Helps to Uncover the Mechanisms of Resistance to AZD9291 and CO-1686 in EGFR-Mutant Lung Adenocarcinoma
    Pirazzoli, Valentina
    Spinozzi, Giulio
    Tenderini, Erika
    Benedicenti, Fabrizio
    Calabria, Andrea
    Montini, Eugenio
    [J]. MOLECULAR THERAPY, 2016, 24 : S83 - S83
  • [2] The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
    Xuejiao Liu
    Xiangyu Chen
    Lin Shi
    Qianqian Shan
    Qiyu Cao
    Chenglong Yue
    Huan Li
    Shengsheng Li
    Jie Wang
    Shangfeng Gao
    Mingshan Niu
    Rutong Yu
    [J]. Journal of Experimental & Clinical Cancer Research, 38
  • [3] The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
    Liu, Xuejiao
    Chen, Xiangyu
    Shi, Lin
    Shan, Qianqian
    Cao, Qiyu
    Yue, Chenglong
    Li, Huan
    Li, Shengsheng
    Wang, Jie
    Gao, Shangfeng
    Niu, Mingshan
    Yu, Rutong
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [4] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [5] ERK pathway activation is associated with acquired resistance to AZD9291, a third-generation irreversible inhibitor targeting EGFR sensitizing (EGFRm plus ) and resistance (T790M) mutations in NSCLC
    Eberlein, Cath
    Al-Kadhimi, Katie
    Ross, Sarah
    Brown, Henry
    Fisher, Paul
    Stetson, Daniel
    Lai, Zhongwu
    Thress, Kenneth
    Dougherty, Brian
    Pao, William
    Cross, Darren
    [J]. CLINICAL CANCER RESEARCH, 2015, 21
  • [6] Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs
    Colclough, N.
    Ballard, P. G.
    Barton, P.
    Chen, K.
    Cross, D. A. E.
    Finlay, M. R. V.
    Han, L.
    Janefeldt, A.
    Johnstrom, P.
    Ward, R. A.
    Wrigley, G. L.
    Yana, Y.
    Yates, J. W. T.
    Zhang, D.
    Zhang, Z.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S28 - S28
  • [7] High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Nanjo, Shigeki
    Ebi, Hiromichi
    Arai, Sachiko
    Takeuchi, Shinji
    Yamada, Tadaaki
    Mochizuki, Satsuki
    Okada, Yasunori
    Nakada, Mitsutoshi
    Murakami, Takashi
    Yano, Seiji
    [J]. ONCOTARGET, 2016, 7 (04) : 3847 - 3856
  • [8] Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
    Shi, Puyu
    Oh, You-Take
    Deng, Liang
    Zhang, Guojing
    Qian, Guoqing
    Zhang, Shuo
    Ren, Hui
    Wu, Grant
    Legendre, Benjamin, Jr.
    Anderson, Emily
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Chen, Mingwei
    Sun, Shi-Yong
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (21) : 6567 - 6579
  • [9] Reversion of mesenchymal behaviour by AZD9291 (osimertinib) in EGFR mutant NSCLC cell lines resistant to first generation EGFR tyrosine kinase inhibitors
    Savastano, B.
    Della Corte, C. M.
    Papaccio, F.
    Giuseppe, V.
    Esposito, G.
    Fasano, M.
    Orditura, M.
    De Vita, F.
    Ciardiello, F.
    Morgillo, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling
    Pan, Yong-Hong
    Lin, Cai-Yu
    Lu, Cong-Hua
    Li, Li
    Wang, Yu-Bo
    Chen, Heng-Yi
    He, Yong
    [J]. CLINICAL RESPIRATORY JOURNAL, 2018, 12 (12): : 2642 - 2652
12